Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth

Signaling Pathways in Liver Cancer

“…Overexpression of c-Met was noted in 20-48% HCC tissues compared to surrounding noncancerous liver tissues, and the overexpression levels correlated with worsening behavior of HCC and decreased 5-year survival in HCC patients (Whittaker et al, 2010;Ueki et al, 1997). A preclinical study reported that inhibition of c-Met by small molecule inhibitor SU11274 decreased HCC cell growth (Inagaki et al, 2011).…”

Perspectives on a combined test of multi serum biomarkers in China: Towards screening for and diagnosing hepatocellular carcinoma at an earlier stage

“…Meanwhile, many researchers recommend that DCP could also be used in assessing the progression of HCC, including serving as an HCC recurrence indicator after curative therapy, a good predictor of the vascular invasion presence and could be used to select liver transplants' recipients, and could facilitate the research of new chemotherapeutic strategies for treating HCC (68)(69)(70)(71)(72)(73)(74). However, currently, DCP is approved in Japan, Korea and Indonesia (75), yet has not been approved in China until now.…”

Des-γ-carboxy prothrombin and c-Met were concurrently and extensively expressed in hepatocellular carcinoma and associated with tumor recurrence

“…Recent studies by the current authors and other researchers found that des-γ-carboxy prothrombin (DCP), an abnormal cytokine secreted by HCC cells, was involved in the activation and regulation of downstream pathways of the c-Met signaling system in vitro and in animal studies (17)(18)(19)(20). Thus, whether or not DCP and c-Met are co-expressed in human HCC and whether their co-expression is correlated with tumor recurrence are questions of great interest.…”